Literature DB >> 19159425

Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus.

Lin Lin, Ashraf S Ibrahim, Beverlie Baquir, Valentina Avanesian, Yue Fu, Brad Spellberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19159425      PMCID： PMC2801022          DOI： 10.1111/j.1574-695X.2008.00531.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN： 0928-8244


× No keyword cloud information.
  12 in total

Review 1.  Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens.

Authors:  I Sugawara
Journal:  Microbes Infect       Date:  2000-08       Impact factor: 2.700

2.  Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo.

Authors:  K M Smith; L Pottage; E R Thomas; A J Leishman; T N Doig; D Xu; F Y Liew; P Garside
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

3.  The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avenissian; Scott G Filler; Carter L Myers; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avanesian; Yue Fu; Carter Myers; Quynh T Phan; Scott G Filler; Michael R Yeaman; John E Edwards
Journal:  J Infect Dis       Date:  2006-06-06       Impact factor: 5.226

5.  IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide.

Authors:  C M Snapper; C Peschel; W E Paul
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

Review 6.  Type 1/Type 2 immunity in infectious diseases.

Authors:  B Spellberg; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-12-15       Impact factor: 9.079

7.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Michael R Yeaman; Lin Lin; Yue Fu; Valentina Avanesian; Arnold S Bayer; Scott G Filler; Peter Lipke; Henry Otoo; John E Edwards
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

9.  Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.

Authors:  Lin Lin; Ashraf S Ibrahim; Valentina Avanesian; John E Edwards; Yue Fu; Beverlie Baquir; Rebecca Taub; Brad Spellberg
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

10.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.

Authors:  Stephanie C Eisenbarth; Oscar R Colegio; William O'Connor; Fayyaz S Sutterwala; Richard A Flavell
Journal:  Nature       Date:  2008-05-21       Impact factor: 49.962
View more
  19 in total

1.  Impact of Staphylococcus aureus USA300 Colonization and Skin Infections on Systemic Immune Responses in Humans.

Authors:  Maria-Luisa Alegre; Luqiu Chen; Michael Z David; Caroline Bartman; Susan Boyle-Vavra; Neha Kumar; Anita S Chong; Robert S Daum
Journal:  J Immunol       Date:  2016-07-11       Impact factor: 5.422

Review 2.  Progress toward a Staphylococcus aureus vaccine.

Authors:  Robert S Daum; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

3.  Luminescent-activated transfected killer cells to monitor leukocyte trafficking during systemic bacterial and fungal infection.

Authors:  Lin Lin; Ashraf S Ibrahim; Beverlie Baquir; Andrew Palosaari; Brad Spellberg
Journal:  J Infect Dis       Date:  2011-11-28       Impact factor: 5.226

Review 4.  Development of a vaccine against Staphylococcus aureus.

Authors:  Brad Spellberg; Robert Daum
Journal:  Semin Immunopathol       Date:  2011-11-14       Impact factor: 9.623

Review 5.  Adaptive immunity to fungi.

Authors:  Akash Verma; Marcel Wüthrich; George Deepe; Bruce Klein
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

6.  A new view on development of a Staphylococcus aureus vaccine: insights from mice and men.

Authors:  Brad Spellberg; Robert Daum
Journal:  Hum Vaccin       Date:  2010-10-01

7.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.

Authors:  Michael R Yeaman; Scott G Filler; Siyang Chaili; Kevin Barr; Huiyuan Wang; Deborah Kupferwasser; John P Hennessey; Yue Fu; Clint S Schmidt; John E Edwards; Yan Q Xiong; Ashraf S Ibrahim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

9.  NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.

Authors:  Ashraf S Ibrahim; Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Clint S Schmidt; John P Hennessey; Samuel W French; Michael R Yeaman; Scott G Filler; John E Edwards
Journal:  Vaccine       Date:  2013-09-21       Impact factor: 3.641

Review 10.  Recent progress in vaccines against fungal diseases.

Authors:  Antonio Cassone; Arturo Casadevall
Journal:  Curr Opin Microbiol       Date:  2012-05-06       Impact factor: 7.934
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.